Related Experiment Video
Updated: Apr 8, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and
Wentao Li1, Jichen Qu1, Zhifei Xu1
11 Department of Thoracic Surgery, Shanghai pulmonary hospital, Tongji University School of Medicine, Shanghai 200433, China ; 2 Department of Thoracic Surgery, Shanghai Changzheng hospital Affiliated to Shanghai Second Military University, Shanghai 200061, China.
Background:
Target therapy is the first-line treatment in lung cancer. The testing of driver gene mutations is crucial for decision of treatment. Many lung cancer patients are in advanced grade, and lose the chance of operation.
Methods:
The tissue used to perform mutation testing is only from biopsy. In order to analysis the difference between surgical resection samples (SRSs) and non-surgical resection samples (NSRSs), 1,357 surgical tissues and 145 biopsy samples histopathologically diagnosed with lung cancer were collected to detect the mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 in this study.
Results:
There were no significant differences of age, gender, and histological type between the two group patients we collected; however, the significant difference was present in grade. More early stage patients were in the surgical group, but more advanced stage lung cancer patients were in non surgical group. In the mutation analysis, we also found no significant differences in all driver genes we detected between the two groups.
Conclusions:
Both surgical resection samples and biopsy samples could be used to perform the testing the driver gene mutation.
Insights
Biopsy and surgical samples are equally effective for detecting lung cancer driver gene mutations. This finding supports using biopsies for crucial treatment decisions, especially for advanced-stage patients.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- Targeted therapy is a primary lung cancer treatment.
- Driver gene mutation testing is essential for treatment selection.
- Advanced lung cancer often precludes surgery.
Purpose of the Study:
- To compare the utility of surgical resection samples (SRSs) and non-surgical resection samples (NSRSs) for driver gene mutation testing in lung cancer.
- To determine if sample type influences mutation detection rates for key lung cancer genes.
Main Methods:
- Collected 1,357 SRSs and 145 NSRSs from lung cancer patients.
- Performed histopathological diagnosis on all samples.
- Detected mutation status for EGFR, KRAS, BRAF, EML4-ALK, and ROS1.
Main Results:
- No significant differences in age, gender, or histological type between SRS and NSRS groups.
- Significant difference in cancer stage: SRS group had more early-stage, NSRS group had more advanced-stage patients.
- No significant differences in mutation status for any of the tested driver genes between the two sample groups.
Conclusions:
- Both surgical resection samples and biopsy samples are suitable for driver gene mutation testing.
- Biopsies are a viable option for mutation analysis, particularly when surgery is not feasible.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018